SINGAPORE, Oct. 02, 2025 — CytoMed Therapeutics (NASDAQ: GDTC), referred to as “CytoMed” or the “Company,” a Singapore-based clinical-stage biopharmaceutical company focused on leveraging its proprietary technologies to develop innovative, cost-effective, donor-derived cell-based immunotherapies for a wide array of cancers, including both blood and solid tumors, is pleased to announce the publication of a preclinical study. The findings are detailed in a research article titled “Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “off-the-shelf” Immunotherapy Approach.” This collaborative research, conducted with The University of Texas MD Anderson Cancer Center (MDACC), suggests the encouraging potential of CytoMed’s allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). This partnership with MDACC was initiated under a research agreement announced in May 2023. The research article is now openly and freely available online at .
“These findings establish the scientific basis for further clinical evaluation of allogeneic donor-derived γδ T cells in treating AML and other malignancies. This will support our efforts to advance our next γδ T cell-based product into clinical trials, following our lead product, CAR-γδ T cells (CTM-N2D), which is currently undergoing a Phase 1 clinical trial in Singapore,” stated Dr. Zeng Jieming, M.D., Ph.D., Chief Scientific and Medical Officer of CytoMed and a co-author of the publication.
Mr. Peter Choo, Chairman of CytoMed, commented, “This research provides additional evidence supporting the application of allogeneic γδ T cells for hematologic malignancies. We are planning to proceed with clinical trials in Southeast Asia to introduce novel immunotherapy options for patients with limited treatment alternatives.”
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed originated as a spin-off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading public sector research and development agency. CytoMed is a clinical-stage biopharmaceutical company dedicated to utilizing its licensed proprietary technologies, specifically gamma delta T cells and iPSC-derived gamma delta Natural Killer T cells, to engineer novel cell-based allogeneic immunotherapies for various human cancers. The development of these innovative technologies is inspired by the clinical success of existing CAR-T therapies in treating hematological malignancies, as well as the current clinical limitations and commercial challenges involved in extending the CAR-T principle to solid tumors. For more details, please visit and follow us on Twitter (“X”) , on , and .
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements encompass declarations regarding plans, objectives, goals, strategies, future events or performance, and underlying assumptions, as well as any statements that are not solely historical facts. When the Company employs terms such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not pertain exclusively to historical matters, it is making forward-looking statements. Forward-looking statements do not guarantee future performance and involve risks and uncertainties that could cause actual outcomes to differ materially from the Company’s expectations discussed within these statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s strategies for developing and commercializing its product candidates; the initiation, scheduling, progress, and results of the Company’s current and future preclinical studies and clinical trials, as well as its R&D programs; the Company’s estimates concerning expenses, future revenue, capital requirements, and needs for additional financing; the Company’s capacity to successfully acquire or license additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or secure further funding, along with assumptions underlying or related to any of the aforementioned, and other risks detailed in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned against placing undue reliance on any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company assumes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
Contact:
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention: Evelyn Tan, Chief Corporate Officer
